Tebentafusp Maintains OS Benefit in HLA-A*02:01+ Uveal MelanomaByPaul Nathan, MBBS, PhD, MCRPApril 20th 2026Paul Nathan, MBBS, PhD, MCRP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01-positive uveal melanoma.